These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 36467495)

  • 1. Progress of oncolytic virotherapy for neuroblastoma.
    Chen XT; Dai SY; Zhan Y; Yang R; Chen DQ; Li Y; Zhou EQ; Dong R
    Front Pediatr; 2022; 10():1055729. PubMed ID: 36467495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers.
    Yamada T; Hamano Y; Hasegawa N; Seo E; Fukuda K; Yokoyama KK; Hyodo I; Abei M
    Curr Cancer Drug Targets; 2018; 18(2):188-201. PubMed ID: 28359239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions.
    Li X; Sun X; Wang B; Li Y; Tong J
    Asian J Pharm Sci; 2023 Jan; 18(1):100771. PubMed ID: 36896445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy.
    Reale A; Calistri A; Altomonte J
    Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis.
    Gao P; Ding G; Wang L
    Transl Cancer Res; 2021 Oct; 10(10):4290-4302. PubMed ID: 35116288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current landscape and perspective of oncolytic viruses and their combination therapies.
    Su Y; Su C; Qin L
    Transl Oncol; 2022 Nov; 25():101530. PubMed ID: 36095879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers.
    Scanlan H; Coffman Z; Bettencourt J; Shipley T; Bramblett DE
    Front Oncol; 2022; 12():940019. PubMed ID: 35965554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Oncolytic Viruses in the Treatment of Melanoma.
    Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
    Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment.
    Lee NH; Kim M; Oh SY; Kim SG; Kwon HC; Hwang TH
    Oncotarget; 2017 Jan; 8(1):1213-1225. PubMed ID: 27901484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
    Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
    Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic virotherapy for neuroblastoma.
    Ramírez M; García-Castro J; Alemany R
    Discov Med; 2010 Nov; 10(54):387-93. PubMed ID: 21122470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).
    Breitbach CJ; Bell JC; Hwang TH; Kirn DH; Burke J
    Oncolytic Virother; 2015; 4():25-31. PubMed ID: 27512667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in oncolytic virus-based cancer therapy.
    Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
    Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune System, Friend or Foe of Oncolytic Virotherapy?
    Filley AC; Dey M
    Front Oncol; 2017; 7():106. PubMed ID: 28589085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.
    Kim MK; Breitbach CJ; Moon A; Heo J; Lee YK; Cho M; Lee JW; Kim SG; Kang DH; Bell JC; Park BH; Kirn DH; Hwang TH
    Sci Transl Med; 2013 May; 5(185):185ra63. PubMed ID: 23677592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical landscape of oncolytic virus research in 2020.
    Macedo N; Miller DM; Haq R; Kaufman HL
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.